Tracers / [18F]FEDAA1106

[18F]FEDAA1106

Also written as [18F]FEDAA1106; [F-18]FEDAA1106
Radionuclide
F-18 t½ 109.77 min
Modality
PET
Production route
—
Stage
investigational
Syntheses indexed
2
Inflammatory diseaseAlzheimer's diseaseDementia other than Alzheimer'sNeuroinflammationDosimetry and biodistribution studies

What it is

Compound class
TSPO PET radioligand
Target / mechanism
18 kDa translocator protein (TSPO) PMID 21732107
Clinical application
Neuroinflammatory diseases (e.g. multiple sclerosis, Alzheimer's disease) PMID 21732107
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
——————22104496
2012 Appl Radiat Isot
using a TRACERlab FX-FN synthesizer
——HPLC+SPE30-60%
yes
—tosyloxy-FEDAA110622469868
2012 Appl Radiat Isot

Need this precursor?We can point you to suppliers for [18F]FEDAA1106, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
—
USP monograph
—
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [18F]FEDAA1106.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with F-18.